Abstract
Due to investigators’ complaints about the volume and limited interpretability of expedited safety reports received in Investigational New Drug (IND) studies, the authors surveyed industry sponsors in late 2009 about their reporting practices. An Internet-enabled survey was submitted to 51 industry sponsors. Ten (20%) complete surveys were returned, 9 of which came from large pharmaceutical/biotechnology companies. Although the response rate in this study was low, considering the consolidation present in this sector, the preponderance of responses from large pharmaceutical companies provides a useful description of the safety reporting practices of a significant sector within the medical products industry. Sponsors described extensive safety-specialized resources for reporting individual events to the FDA and IND investigators. Aggregate reports, when prepared, were provided to the FDA but rarely to investigators. Sponsors reported receiving complaints from investigators about excessive volume and limited relevance of individual safety reports. These data suggest that investigators would likely benefit if industry sponsors decreased reporting of individual cases that are not readily interpretable and instead reported meaningful safety information from aggregate analyses.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Code of Federal Regulations Volume 21, Section 312.32, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32, accessed April 23, 2014.
Duley L, Antman K, Arena J, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008;5(1):40–48.
Food and Drug Administration. Guidance for clinical investigators, sponsors, and IRBs: adverse event reporting to IRBs—improving human subject protection. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126572.pdf. Published January 2009.
Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials. 2009;6(5):430–440.
Clinical Trial Transformation Initiative website. www.ctti-clinicaltrials.org. Accessed January 30, 2013.
Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule. Fed Regist. 2010;75(188):59935–59963.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Safety reporting requirements for INDs and BA/BE studies. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM227351.pdf. Published December 2012. Accessed December 18, 2013.
Food and Drug Administration. Guidance for industry: E2F development safety update report. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073109.pdf. Published August 2011. Accessed January 30, 2013.
Archdeacon P, Grandinetti C, Vega JM, Balderson D, Kramer JM. Optimizing expedited safety reporting for drugs and biologics subject to an Investigational New Drug Application [published online November 7, 2013]. Therapeutic Innovation & Regulatory Science. doi:https://doi.org/10.1177/2168479013509382
Kramer JM, Vock D, Greenberg HE, et al. Investigators’ experience with expedited safety reports prior to the FDA’s final IND safety reporting rule [published online January 30, 2014]. Therapeutic Innovation & Regulatory Science. doi:https://doi.org/10.1177/2168479013520160.
Flynn KE, Kramer JM, Dombeck CB, Weinfurt KP. Participants’ perspectives on safety monitoring in clinical trials. Clin Trials. 2013;10:552–559.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sethi, S.S., Kramer, J.M., Gagnon, S. et al. Industry Practices for Expedited Reporting to Investigators Conducting Research Under an IND. Ther Innov Regul Sci 48, 741–748 (2014). https://doi.org/10.1177/2168479014532260
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479014532260